Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 5/20 | 0.53 |
| ▸ | PREP | P48147 | 4/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL889092 | 0.90 | GRIN2B (0.53) | GRIN2BPREPTSHRL3MBTL1KDM4E | |
| SCHEMBL1597775 | 0.84 | HCRTR2 (0.48) | GRIN2BTSHRALDH1A1NPSR1 | |
| SCHEMBL1597774 | 0.84 | HCRTR2 (0.48) | GRIN2BTSHRALDH1A1NPSR1 | |
| SCHEMBL12567192 | 0.82 | TSHR (0.62) | PREPTSHRL3MBTL1KDM4ELMNA | |
| SCHEMBL1598802 | 0.81 | CYP2D6 (0.46) | CYP2D6ALDH1A1 | |
| SCHEMBL34473807 | 0.79 | PREP (0.54) | PREPTSHRL3MBTL1KDM4ELMNA | |
| SCHEMBL22158059 | 0.79 | PREP (0.54) | PREPTSHRL3MBTL1KDM4ELMNA | |
| SCHEMBL13060873 | 0.79 | PREP (0.54) | PREPTSHRL3MBTL1KDM4ELMNA | |
| SCHEMBL12810103 | 0.79 | FPR3 (0.49) | CYP2D6ALDH1A1 | |
| SCHEMBL4260135 | 0.79 | VNN1 (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110064697-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-03-17 | — | — | US | disclosed |
| US-20110064697-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110064697-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, EIF2AK2, SLC10A1 | GRIN2B 4821/4885PREP 519/4885TSHR 4674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.